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Abstract. – 99mTc-sestamibi has been in-
vestigated as a potential viability marker; initial
studies have shown good concordance between
201Tl and 99mTc-sestamibi activities in both vi-
able and nonviable myocardium. However, as-
sessment of myocardial viability by 99mTc-ses-
tamibi remains controversial for tissue recovery
after revascularization. Here, we present a pa-
tient with several regions of severely dimin-
ished and irreversible (defect persisting in both
early and delay images of each set scanning)
defects on initial scan which were dissolved
completely on the follow up scan after an inter-
vention. In a 75 year-old Asian woman with
acute myocardial infarction who received throm-
bolytic therapy and subjected to percutaneous
coronary angiography (PCI) on day 28 after
acute myocardial infarction(MI), resting 99mTc-
sestamibi SPECT was applied on day 4 (initial
scan) and 138 (follow up scan) after acute MI at
30 and 180 min after injection of tracer (740
MBq); Two-dimentional echocardiography was
carried out at the same time. On the initial im-
age set, there was irreversible defects in the
apex, anteroapical, inferoapical, anteroseptal,
septal and also anterior walls, while the follow
up image was normal in all regions.The angiog-
raphy intervention showed just significant
stenosis on left anterior descending (LAD) ves-
sel (95%). This may highlight the failure of
99mTc-sestamibi as a marker of myocardial via-
bility and also mandate further validating of the
procedure with follow up scan or other modali-
ties for myocardial viability investigation.
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Abbreviations
PCI = percutaneous coronary intervention;
MII = myocardial infarction;
LADI = left anterior descending;
PETI = positron emission tomography;
SPECTI = single photon emission computed
tomography;
ECGI = electrocardiogram;
EFI = ejection fraction;
LVDDI = left ventricular end-diastolic cavity
dimension;
201TlI = thallium-201;
FDG-PETI = fluorodeoxyglucose positron
emission tomography
Introduction
Assessment of myocardial viability in patients
with an acute coronary artery disease plays an im-
portant role in making decision to refer these pa-
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bolytic therapy after 4 hours onset of chest pain
and subjected to percutaneous coronary inter-
vention (PCI) on day 28 after acute MI, resting
99mTc-sestamibi SPECT was applied on day 4
(initial scan) and 138 (follow up scan) after
acute MI at 30 and 180 min after injection of
tracer (740 MBq). Two-dimensional echocar-
diography also was carried out at the same
time5. She had diabetes mellitus (DM) and hy-
perlipidemia but she didn’t have hypertension,
smoking and also history of ischemic heart dis-
ease (IHD); creatine phosphokinase (CPK) was
548 IU/L. Based on the electrocardiogram
(ECG), anterior MI and involvement of LAD
territory was determined. On first echocardiog-
raphy, ejection fraction (EF): 47 %; left ventric-
ular end-diastolic cavity dimension (LVDD):
4.45; moderate anteroseptal hypokinesia and al-
so echocardiography score: 4 was seen. Second
echocardiography showed EF: 61%; LVDD:
3.77; mild septal hypokinesia without any
valvular abnormality; also echocardiography
score: 1. On the initial image set, there was irre-
versible defects in the apex, anteroapical, in-
feroapical, anteroseptal, septal and also anterior
walls (Figure 1), while the follow up image was
normal in all regions (Figure 2). The main
scintigraphic data are shown in Table I. The an-
giography showed just significant stenosis on
LAD vessel (95%). The patient underwent PCA
on LAD.
tients for coronary revascularization. Positron
emission tomography (PET) is considered by
some to be the gold standard to ascertain the pres-
ence of myocardial viability1, but its high cost and
limited availability may prevent its using as a rou-
tine practice modality. Heretofore, 201Tl has been
considered the preferred agent to detect viable
myocardium, with one of several possible imaging
strategies2. 99mTc-sestamibi has also been investi-
gated as a potential viability marker. Initial studies
have shown a good concordance between 201Tl
and 99mTc-sestamibi activities in both viable and
nonviable myocardium1. However, assessment of
myocardial viability by 99mTc-sestamibi remains
controversial for tissue recovery after revascular-
ization3,4.In our study concerning resting 99mTc-
sestamibi single photon emission computed to-
mography (SPECT) in the recovery of myocardial
function in patients with acute myocardial infarc-
tion5, we found a patient with several regions of
severely diminished and irreversible defects on
initial scan which were dissolved completely on
the follow up scan after an intervention. This case
presentation may indicate 99mTc-sestamibi as a
myocardial viability marker along with further in-
tensifying the need for 99mTc-sestamibi validat-
ing criteria for myocardial viability.
Case Presentation
In a 75 year-old Asian woman with acute my-
ocardial infarction (MI) who received throm-
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Figure 1. The initial set images
of the patient showed irreversible
defects in the apex, anteroapical,
inferoapical, anteroseptal, septal
and also anterior walls. The upper
rows indicate 30 minute rest
99mTc-sestamibi SPECT images
and lower rows 180 minutes rest
99mTc-sestamibi SPECT images.
Discussion
There are several investigations regarding the
role of Tc-99m sestamibi in determination of vi-
able myocardium. A good correlation has been
described between the quantified sestamibi ac-
tivity and the extent of viable myocardium de-
termined by morphometric studies1,3. In a previ-
ous study, there was a complete correlation be-
tween two agents in the prediction of viability2.
Tc-99m sestamibi had a positive predictive val-
ue of 90% and a negative predictive value of
91% for improvement of left ventricular func-
tion6. In comparison of myocardial uptake of
201Tl with rest 99mTc-sestamibi uptake in 20
patients with a mean left ventricular ejection
fraction of 33 ± 2%, comparable worth of rest
99mTc-sestamibi SPECT for viability assess-
ment was suggested7.
On the other hand, in patients with a previous
MI, estimation of perfusion defect size deter-
mined by Tc-99m sestamibi exceeded that of
13N ammonia. The difference in defect size be-
tween Tc-99m sestamibi and 13N ammonia has
been significantly greater in patients with viable
vs. nonviable walls8. In addition, 18F fluorine-
deoxyglucose (18F-FDG) evidence of viability
had still been present in 50% of walls with
99mTc-sestamibi activity <40% and no signifi-
cant difference in the 99mTc-sestamibi activity
was described in viable and nonviable walls8. In
another study, Altehoefer et al4 investigated the
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Complete improvement in the 99mTc-MIBI myocardial SPECT
Figure 2. The follow up set
images of the patient showed no
abnormal perfusion. The upper
rows indicate 30 minute rest
99mTc-sestamibi SPECT im-
ages and lower rows 180 min-
utes rest 99mTc-sestamibi
SPECT images.
30 min 180 min 30 min 180 min
Percent uptake territory initial set initial set follow up set follow up set
SPS 35 32 0 0
LHR 0.28 0.25 0.29 0.29
CMR 0.114 0.084 0.476 0.438
LAD 37 40 82 78
RCA 50 51 73 80
LCX 78 80 84 8
Table I. The main scintigraphic findings of the patient.
SPS, sum perfusion score; LHR, lung heart ratio; CMR, cavity to myocardium ratio; LAD, left anterior descending artery;
RCA, right coronary artery, LCX, left circumflex artery.
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relationship between 99mTc-sestamibi uptake at
rest and preserved or absent uptake of 18F-FDG
in 111 patients with coronary artery disease, in
which segments with a normalized 18F-FDG up-
take >70% defined as viable while segments with
a 18F-FDG uptake <50% were designated as
nonviable. They concluded that myocardial
99mTc-sestamibi uptake seems to be a sign of
myocardial blood flow rather than myocardial vi-
ability.
Although some works such as nitrate admin-
istration at rest phase, combined use of ses-
tamibi perfusion/wall motion scan and the de-
velopment of new software might improve the
results in the setting of myocardial viability, a
reliable judgment about myocardial viability
cannot be made upon it solely9. The results of
this case presentation concordantly suggest that
99mTc-sestamibi underestimates myocardial
viability, compared to the accepted standards of
thallium (rest-redistribution or stress-reinjec-
tion protocols), 18F-FDG PET and also in the
prediction of left ventricular functional recov-
ery after revascularization10.
Conclusions
This case showed complete improvement of
several irreversible defects on 99mTc-sestamibi
scintigraphy, suggesting its underestimation of
myocardial viability in the prediction of left ven-
tricular functional recovery after revasculariza-
tion. In addition, may show that patients with
moderate and severe 99mTc-sestamibi defects at




We are indebted to the technologists at our Department
for data acquisition and other technical support.
References
1) DAKIK HA, HOWELL JF, LAWRIE GM, ESPADA R, WEIL-
BAECHER DG, HE ZX, MAHMARIAN JJ, VERANI MS. As-
sessment of myocardial viability with 99mTc-ses-
tamibi tomography before coronary bypass graft
surgery: correlation with histopathology and post-
operative improvement in cardiac function. Circu-
lation 1997; 96: 2892-2898.
2) UDELSON JE, COLEMAN PS, METHERALL J, PANDIAN NG,
GOMEZ AR, GRIFFITH JL, SHEA NL, OATES E, KONSTAM
MA. Predicting recovery of severe regional ven-
tr icular dysfunction. Comparison of resting
scintigraphy with 201Tl and 99mTc-sestamibi.
Circulation 1994; 89: 2552-2561.
3) MEDRANO R, LOWRY RW, YOUNG JB, WEILBAECHER DG,
MICHAEL LH, AFRIDI I, HE ZX, MAHMARIAN JJ, VERANI
MS. Assessment of myocardial viability with
99mTc sestamibi in patients undergoing cardiac
transplantation. A scintigraphic/pathological study.
Circulation 1996; 94: 1010-1017.
4) ALTEHOEFER C, VOM DAHL J, BIEDERMANN M, UEBIS R,
BEILIN I, SHEEHAN F, HANRATH P, BUELL U. Significance
of defect severity in technetium-99m-MIBI SPECT
at rest to assess myocardial viability: comparison
with fluorine-18-FDG PET. J Nucl Med 1994; 35:
569-574.
5) NESHANDAR E, PORPIRANFAR MA, GHAMIRI SMR, JAVADI
H. Role of the left ventricular cavity-to-myocardi-
um count ratio in resting technetium-99m-Ses-
tamibi SPECT in the recovery of myocardial func-
tion after thrombolytic therapy in patients with
acute myocardial infarction. Int J Low Radiation
2007; 4: 33-42.
6) SCHNEIDER CA, VOTH E, GAWLICH S, BAER FM, HORST
M, SCHICHA H, ERDMANN E, SECHTEM U. Signifi-
cance of rest technetium-99m sestamibi imag-
ing for the prediction of improvement of left ven-
tricular dysfunction after Q wave myocardial in-
farction: importance of infarct location adjusted
thresholds. J Am Coll Cardiol 1998; 32: 648-
654.
7) KAUFFMAN GJ, BOYNE TS, WATSON DD, SMITH WH,
BELLER GA. Comparison of rest thallium-201 imag-
ing and rest technetium-99m sestamibi imaging
for assessment of myocardial viability in patients
with coronary artery disease and severe left ven-
tricular dysfunction. J Am Coll Cardiol 1996; 27:
1592-1597.
8) SAWADA SG, ALLMAN KC, MUZIK O, BEANLANDS RS,
WOLFE ER, JR., GROSS M, FIG L, SCHWAIGER M.
Positron emission tomography detects evidence
of viability in rest technetium-99m sestamibi de-
fects. J Am Coll Cardiol 1994; 23: 92-98.
9) BISI G, SCIAGRA R, SANTORO GM, FAZZINI PF. Rest
technetium-99m sestamibi tomography in com-
bination with short-term administration of ni-
trates: feasibility and reliability for prediction of
postrevascularization outcome of asynergic
territories. J Am Coll Cardiol 1994; 24:1282-
1289.
10) CORNEL JH, ARNESE M, FORSTER T, POSTMA-TJOA J, REI-
JS AE, FIORETTI PM. Potential and limitations of Tc-
99m sestamibi scintigraphy for the diagnosis of
myocardial viability. Herz 1994; 19: 19-27.
H. Javadi, M.A. Porpiranfar, S. Semnani, S. Jallalat, P. Yavari, M. Mogharrabi, et al.
